Patents Assigned to ICN Pharmaceuticals
-
Patent number: 6642206Abstract: Novel monocyclic L-Nucleoside compounds have the general formula Embodiments of these compounds are contemplated to be useful in treating a wide variety of diseases including infections, infestations, neoplasms, and autoimmune diseases. Viewed in terms of mechanism, embodiments of the novel compounds show immunomodulatory activity, and are expected to be useful in modulating the cytokine pattern, including modulation of Th1 and Th2 response.Type: GrantFiled: April 9, 2002Date of Patent: November 4, 2003Assignee: ICN Pharmaceuticals, Inc.Inventors: Kanda Ramasamy, Robert Tam, Devron Averett
-
Patent number: 6613896Abstract: C-nucleosides are synthesized by a method in which a sugar is derivatized in a single step to provide a heterocycle at the C1 position, and then the heterocycle is aromatized in another single step. In one class of preferred embodiments a cyano sugar is converted into thiocarboxamide, and subsequently condensed to form an azole ring. In a second class of preferred embodiments a cyano sugar is condensed with an amino acid to provide the azole ring. In a third class of preferred embodiments a halo sugar is condensed with a preformed heterocycle to provide the azole ring.Type: GrantFiled: June 6, 2000Date of Patent: September 2, 2003Assignee: ICN Pharmaceuticals, Inc.Inventors: Kandasamy Ramasamy, Rajanikanth Bandaru, Devron Averett
-
Patent number: 6573248Abstract: Novel monocyclic L-Nucleoside compounds have the general formula Embodiments of these compounds are contemplated to be useful in treating a wide variety of diseases including infections, infestations, neoplasms, and autoimmune diseases. Viewed in terms of mechanism, embodiments of the novel compounds show immunomodulatory activity, and are expected to be useful in modulating the cytokine pattern, including modulation of Th1 and Th2 response.Type: GrantFiled: December 31, 2001Date of Patent: June 3, 2003Assignee: ICN Pharmaceuticals, Inc.Inventors: Kandasamy Ramasamy, Robert Tam, Devron Averett
-
Patent number: 6552183Abstract: Novel monocyclic L-Nucleoside compounds have the general formula Embodiments of these compounds are contemplated to be useful in treating a wide variety of diseases including infections, infestations, neoplasms, and autoimmune diseases. Viewed in terms of mechanism, embodiments of the novel compounds show immunomodulatory activity, and are expected to be useful in modulating the cytokine pattern, including modulation of Th1 and Th2 response.Type: GrantFiled: August 7, 2000Date of Patent: April 22, 2003Assignee: ICN Pharmaceuticals, Inc.Inventors: Kandasamy Ramasamy, Robert Tam, Devron Averett
-
Patent number: 6509320Abstract: Novel purine L-nucleoside compounds are disclosed, in which both the purine rings and the sugar are either modified, functionalized or both. The novel compounds or pharmaceutically acceptable esters or salts thereof may be used in pharmaceutical compositions, and such compositions may be used to treat an infection, an infestation, a neoplasm, or an autoimmune disease. The novel compounds may also be used to modulate aspects of the immune system, including modulation of Th1 and Th2.Type: GrantFiled: June 15, 2000Date of Patent: January 21, 2003Assignee: ICN Pharmaceuticals, Inc.Inventors: Guangyi Wang, Robert Tam, Devron Averett
-
Patent number: 6479463Abstract: Novel purine L-nucleoside compounds are disclosed, in which both the purine rings and the sugar are either modified, functionalized or both. The novel compounds or pharmaceutically acceptable esters or salts thereof may be used in pharmaceutical compositions, and such compositions may be used to treat an infection, an infestation, a neoplasm, or an autoimmune disease. The novel compounds may also be used to modulate aspects of the immune system, including modulation of Th1 and Th2.Type: GrantFiled: June 16, 2000Date of Patent: November 12, 2002Assignee: ICN Pharmaceuticals, Inc.Inventors: Guangyi Wang, Robert Tam, Devron Averett
-
Publication number: 20020095033Abstract: Novel monocyclic L-Nucleoside compounds have the general formula 1Type: ApplicationFiled: December 31, 2001Publication date: July 18, 2002Applicant: ICN Pharmaceuticals, Inc.Inventors: Kandasamy Ramasamy, Robert Tam, Devron Averett
-
Patent number: 6403566Abstract: Conformationally restricted 2′, 4′—bridged nucleoside analogues are described herein. The compounds can be prepared by cyclization at C2′ and C4′ of nucleosides through a linker or linking molecule. These novel nucleosides have a desired, locked sugar pucker and are potentially useful as pharmaceutical ingredients. Oligonucleotides composed of these novel nucleosides are useful for oligonucleotide therapeutic and diagnostic compounds.Type: GrantFiled: December 1, 1999Date of Patent: June 11, 2002Assignee: ICN Pharmaceuticals, Inc.Inventor: Guangyi Wang
-
Patent number: 6211201Abstract: A quaternary ammonium cholinergic agent is complexed with a multivalent anion, or with multiple monovalent anions. The complex may be administered orally to a patient to treat pain, or for some other purpose. Numerous modifications are contemplated, including modifications to the ring structure of the compound, substitution and functionalization of the ring. Other contemplated modifications include the use of different anions, including various monovalent and polyvalent anions, and both organic and inorganic anions. The compounds have utility as cholinergic agents, and especially in the treatment of mysasthenia gravis, chest pain, and carpal tunnel syndrome.Type: GrantFiled: June 29, 1999Date of Patent: April 3, 2001Assignee: ICN Pharmaceuticals, Inc.Inventors: Colin Granger, Robert Orr, Kandasamy Ramasamy
-
Patent number: 6191266Abstract: A number of modified nucleosides are disclosed composed of modified sugar moieties which contain substituents at C1 and C4 positions, or branched substituents at C3 and C5 positions of deoxyribose or ribose. Each nucleoside is converted to or properly protected and then converted to the corresponding phosphoramidites. These phosphoramidites are used to assemble oligonucleotides in which there is at least one of the forenoted nucleosides. These sugar modified oligonucleotides have the potential to be used as antisense therapies since they are expected to enhance nuclease resistance and cellular uptake while they maintain sequence-specificity and affinity to nucleic acid targets in vitro or in vivo.Type: GrantFiled: December 16, 1996Date of Patent: February 20, 2001Assignee: ICN Pharmaceuticals, Inc.Inventor: Guangyi Wang
-
Patent number: 6150337Abstract: Ribavirin is employed in a manner which is effective to modulate lymphokine expression in activated T cells. In particular, Ribavirin is used to suppress Type 2-mediated T cell responses and promote Type 1-mediated T cell response. Thus, instead of administering Ribavirin in its well-recognized role as an anti-viral agent, Ribavirin is herein used in the treatment of imbalances in lymphokine expression. Such imbalances may be found to be concomitants of allergic atopic disorders such as allergic asthma and atopic dermatitis, helminth infection and leishmaniasis, and various primary and secondary immunodeficiencies, which may or may not also be associated with viral infection.Type: GrantFiled: September 18, 1998Date of Patent: November 21, 2000Assignee: ICN Pharmaceuticals, Inc.Inventor: Robert Tam
-
Patent number: 6130326Abstract: Novel monocyclic L-Nucleoside compounds have the general formula ##STR1## Embodiments of these compounds are contemplated to be useful in treating a wide variety of diseases including infections, infestations, neoplasms, and autoimmune diseases. Viewed in terms of mechanism, embodiments of the novel compounds show immunomodulatory activity, and are expected to be useful in modulating the cytokine pattern, including modulation of Th1 and Th2 response.Type: GrantFiled: April 14, 1999Date of Patent: October 10, 2000Assignee: ICN Pharmaceuticals, Inc.Inventors: Kandasamy Ramasamy, Robert Tam, Devron Averett
-
Patent number: 6110453Abstract: A polymeric composition capable of releasing nitric oxide including a polymer and a nitric oxide-releasing N.sub.2 O.sub.2.sup.- functional group bound to the polymer; pharmaceutical compositions including the polymeric composition; and methods for treating biological disorders in which dosage with nitric oxide is beneficial. The compositions can be used as and/or incorporated into implants, injectables, condoms, prosthesis coatings, patches, and the like for use in a wide variety of medical applications.Type: GrantFiled: January 26, 1998Date of Patent: August 29, 2000Assignees: The United States of America as represented by the Department of Health and Human Services, ICN Pharmaceuticals, Inc.Inventors: Larry K. Keefer, Joseph A. Hrabie
-
Patent number: 6083482Abstract: Conformationally restricted 3',5'-bridged nucleoside analogues are described herein. The compounds can be prepared by cyclization at C3' and C5' of nucleosides through a linker or linking molecule. The nucleoside bases may be modified or unmodified. The nucleosides can be used as oligonucleotide building blocks or as small molecule pharmaceutical ingredients.Type: GrantFiled: May 11, 1999Date of Patent: July 4, 2000Assignee: ICN Pharmaceuticals, Inc.Inventor: Guangyi Wang
-
Patent number: 6063772Abstract: Ribavirin is administered to a patient in a dosage range which is effective to modulate lymphokine expression In activated T cells. In particular, ribavirin is used to suppress Th2-mediated T cell responses and promote Th1-mediated T cell response. Thus, instead of administering ribavirin in its well-recognized role as an anti-viral agent, ribavirin is herein used in the treatment of imbalances in lymphokine expression. Such imbalances may be found to be concomitants of allergic atopic disorders such as allergic asthma and atopic dermatitis, helminth Infection and leishmaniasis, and various primary and secondary immunodeficiencies, which may or may not also be associated with viral infection.Type: GrantFiled: June 15, 1998Date of Patent: May 16, 2000Assignee: ICN Pharmaceuticals, Inc.Inventor: Robert C. Tam
-
Patent number: 6017898Abstract: Oligonucleotides are provided which are effective in inhibiting the growth, metastasis and/or angiogenesis of tumors, including particularly melanoma and/or lung cancer. Methods are also provided for use of these oligonucleotides in the treatment of diseases.Type: GrantFiled: April 6, 1998Date of Patent: January 25, 2000Assignee: ICN Pharmaceuticals, Inc.Inventors: Zbigniew Pietrzkowski, Dariusz Cieslak, Gordana Olbina
-
Patent number: 5990299Abstract: Neoplastic cells which over-express CD44, including especially non-small cell lung cancer and melanoma cancer cells, are treated with antisense oligonucleotides to control CD44 expression. Test results show that the claimed oligonucleotides significantly decreases cell growth in a CD44 sequence specific manner of lung cancer or melanoma cells, or both, but are largely non-toxic to normal cells. Examples of dosing in a clinical setting are provided.Type: GrantFiled: August 14, 1995Date of Patent: November 23, 1999Assignee: ICN Pharmaceuticals, Inc.Inventors: Sabera Ruzdijic, Zbigniew Pietrzkowski, Dariusz Cieslak
-
Patent number: 5969135Abstract: The present invention provides various novel oligonucleotide analogs having one or more properties that make the subject compounds superior to conventional oligonucleotides for use in procedures employing oligonucleotides. The compounds of the invention are oligonucleotide analogs in which the furanose ring of a naturally occurring nucleic acid is replaced with an amino acid or a modified amino alcohol residue. Some embodiments of the novel compounds of the invention are particularly useful for the antisense control of gene expression. The compounds of the invention may also be used as nucleic acid hybridization probes or as primers. Another aspect of the invention is to provide monomeric precursors of the oligonucleotide analogs of the invention. These monomeric precursors may be used to synthesize the subject polynucleotide analogs. Another aspect of the invention is to provide formulations of the subject polynucleotide analogs that are designed for the treatment or prevention of disease conditions.Type: GrantFiled: November 2, 1995Date of Patent: October 19, 1999Assignee: ICN Pharmaceuticals, Inc.Inventors: Kandasamy Ramasamy, Wilfried E. Seifert
-
Patent number: 5907036Abstract: Novel procedures for obtaining ribo-C-nucleosides, including especially 2-.beta.-D-ribofuranosylthiazole-4-carboxylamide (tiazofirin) and 2-.beta.-D-ribofuranosylselenazole-4-carboxylamide (sylenazofurin) and synthesis intermediates thereof. The novel procedures involve introducing a cyano group at the 1' position of a ribose, directly or indirectly converting the cyano group to HN.dbd.C--OR.sub.1 or thicarboxylamide wherein R.sub.1 is a lower alkyl, forming the group which substituted for the cyano group into a heterocyclic ring containing an ester, and converting the ester into an amide.Type: GrantFiled: February 20, 1996Date of Patent: May 25, 1999Assignee: ICN Pharmaceuticals, Inc.Inventors: Kandasamy Ramasamy, Arthur F Lewis, Roland K Robins, deceased, Natarajan Raju, Ramesh Bharadwaj, Vjera Pejanovic
-
Patent number: D408957Type: GrantFiled: August 30, 1996Date of Patent: April 27, 1999Assignee: ICN Pharmaceuticals, Inc.,Inventor: Joseph Sandor